BidaskClub upgraded shares of Exelixis (NASDAQ:EXEL) from a hold rating to a buy rating in a report published on Friday.

A number of other equities analysts have also commented on the company. Stifel Nicolaus reissued a hold rating and issued a $26.00 price objective on shares of Exelixis in a research note on Thursday, September 7th. Leerink Swann lowered Exelixis from an outperform rating to a market perform rating and reduced their price objective for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. TheStreet raised Exelixis from a c+ rating to a b- rating in a research note on Wednesday, October 18th. Zacks Investment Research upgraded Exelixis from a hold rating to a strong-buy rating and set a $35.00 target price for the company in a research report on Tuesday. Finally, Piper Jaffray Companies restated a buy rating and set a $29.00 target price on shares of Exelixis in a research report on Sunday, September 10th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $32.13.

Exelixis (NASDAQ EXEL) traded down $0.27 during trading on Friday, reaching $31.62. The company’s stock had a trading volume of 2,177,449 shares, compared to its average volume of 2,430,000. The firm has a market capitalization of $9,280.00, a price-to-earnings ratio of 64.53, a P/E/G ratio of 0.96 and a beta of 1.88. Exelixis has a one year low of $14.94 and a one year high of $32.50.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to analyst estimates of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The business’s revenue was up 145.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.04) earnings per share. sell-side analysts anticipate that Exelixis will post 0.49 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new stake in Exelixis in the third quarter valued at about $120,000. Fisher Asset Management LLC bought a new stake in Exelixis in the third quarter valued at about $213,000. Caxton Associates LP bought a new stake in Exelixis in the second quarter valued at about $227,000. Private Advisor Group LLC bought a new stake in Exelixis in the second quarter valued at about $247,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Exelixis in the third quarter valued at about $236,000. Institutional investors own 81.15% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Exelixis (EXEL) Upgraded to Buy at BidaskClub” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/exelixis-exel-upgraded-to-buy-at-bidaskclub/1797477.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with Analyst Ratings Network's FREE daily email newsletter.